Wall Street 2026 Earnings: Big Banks Beat Expectations as AI Deals Rise
U.S. financial giants say they made money in the first quarter thanks to a rise in investment banking. At the same time, Novo Nordisk and OpenAI announce a historic agreement to use AI to find new drugs.
On Tuesday, the big players on Wall Street sent a clear message to start the 2026 Q1 earnings season: the time of high-interest-rate stagnation is over, and an AI-driven dealmaking boom is on the way.Reports from JPMorgan Chase, Goldman Sachs, and Citigroup all above expectations, showing a big rise in advising fees and equity underwriting that hasn't happened in almost three years.A lot of the activity is being blamed on a wave of efficiency mergers, in which old companies are aggressively buying AI startups to bring their processes up to date.Even the most optimistic bulls on the floor were shocked when JPMorgan Chase, the largest bank in the US, said its net income had gone up.In a prepared statement, CEO Jamie Dimon said that the rebound in capital markets is real and will last, even if the global economy is still very complicated.A lot of that bounce is because of the IT sector. AI businesses that have received venture capital are now becoming major acquisition targets for Fortune 500 organizations that want to add generative capabilities straight to their supply chains.But a historic announcement from the healthcare and IT sectors almost overshadowed the financial figures from the morning. Novo Nordisk, the huge biopharmaceutical company that makes the popular GLP-1 weight-loss medications, has teamed up with OpenAI in a strategic discovery-to-delivery alliance. The goal of the partnership is to use huge, private version of OpenAI's newest reasoning model to map complicated protein interactions at rates that were thought to be unattainable before.The agreement is a huge step forward for OpenAI,taking it further away from chatbots for consumers and deeper into specialized enterprise infrastructure.Novo Nordisk's agreement is a brilliant move on both the defensive and offensive fronts.The company thinks that by adding generative AI to its research and development pipeline, they would be able to find early-stage medication candidates up to 40% faster.A spokeswoman for Novo Nordisk noted during the press conference,We're not just using AI to write code or summarize emails.We're using it to solve biological puzzles that have been bothering scientists for decades.The ramifications were noticed right away throughout the S&P 500 following the opening bell.Investors believed that the Novo-OpenAI transaction would lead to further high-value partnerships in the biotech and energy industries,which drove up the price of financial equities.Morgan Stanley analysts said that this secular shift in business strategy is giving the market the basic underpinning it needed in late 2025.Even if some were hopeful,the day's outcomes showed that the financial sector is becoming more and more different.The Big Three had record profits,but mid-sized regional lenders are still having trouble since the commercial real estate market is slowing down and the costs of going digital are going up.There is a growing gap between people who can pay for big changes led by AI and people who cannot. This is making the economy move at two speeds, which federal regulators are said to be keeping a careful eye on.The focus stays on how long this momentum will last as the trade day goes on.There are more than 40 S&P 500 businesses that will report profits in the next 48 hours. This is how the story on Wall Street is being written for 2026. For now, investors have a reason to stay bullish as spring arrives since banks have strong balance sheets and there are high-stakes tech partnerships.
